Roche partners with Zealand Pharma to push forward obesity drug

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.

The Swiss pharma giant and the Danish biotech will now work together to develop Zealand’s drug candidate petrelintide, aiming to test it on its own and in combination with Roche’s experimental CT-388.

The agreement includes additional payments based on certain clinical and sales goals being met, totaling up to $5.3 billion.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

New biomaterial could change the way human tissue can be grown in the lab

Scientists at UNSW Sydney have created a new material that could change the way human tissue can be grown in the lab and used in

October 25, 2023

UZH researchers harness AI to detect antibiotic resistance

Researchers at the University of Zurich (UZH) have used artificial intelligence (AI) to help identify antibiotic-resistant bacteria.

October 17, 2024

Overcoming limitations of traditional CVD drugs

Announcing a new publication for Acta Materia Medica journal. Cardiovascular diseases (CVDs) pose a significant threat to human health due to the high mortality and

January 15, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.